CMS makes it of­fi­cial: Cov­er­age for new Alzheimer's drugs once full ap­provals ar­rive

As Con­gres­sion­al and ad­vo­ca­cy group pres­sure has been heat­ed, the Cen­ters for Medicare and Med­ic­aid Ser­vices reaf­firmed to­day that if amy­loid-tar­get­ed drugs to slow the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER